...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith cost basis

froh

I haven't checked my Zenith share prices lately but in the past they keep changing for some unknown reason. The stock is privately held so there is no market to set the prices. There is a private market for these shares but I very much doubt that my trading company takes that into account.

Even the valuations presented by Zenith management changed dramatically in the recent past doubling or tripling and then dropping back down with no rhyme or reason.

We'll only get an idea if Don gets this stock listed on the TSXand/or NASDAQ and recently he has shown no interest in this. Why would he. It costs money and the listing company must meet qualifications. At this stage there is no evidence that zen3694 does anything (other than in the agar plate on certain cells and some animal tests). So if he lists it it will probably come out at a very low price and that is of little value in terms of raising public money to finance research. 

Seems to me that Don is going to be back into the old dilema of raising private money through an LOC, private money, finding a partner, etc.

If the zen3694 trial on mCRPC shows strong promise, particularly in the combo therapy with enzalutimide, there may be an interest from Pfizer or another BP. However, we have seen very limited data on this trial. Silence has been the order of the day. The slience makes me suspicious (but that is a natural reaction to lack of information).

As I understand it there are a number of companies experimenting with epigenetics and treatment of cancers and there are no breakthroughs that I am aware of. To me it is a good sign that multiple companies are experimenting in this area.

I remember in one of Don's presentations there was a schematic explaining why they hypothesize zen3694 could allow enzalutimide to regain some of it's effectiveness. As a non scientists I like the idea that Zenith seems focussed and may have picked the right type of cancer to tackle (who knows) and that  their experiment is designed with a specific hypothesis in mind. It will be extremely exciting if zen3694 actually has a positive impact on treating mCRPC on it's own without enzalutimide.

My bottom line at this stage is that this is a very new science and there are probably many years of learning ahead before significant results are achieved. 

I speculate that Don would love to have the apabetalone DM/CVD BoM trial turn into an economic success and see royalties flow into Zenith Capital but my guess is that won't start happening until after 2020 earliest. Sure hope I am wrong.

Finally both Zenith and RVX are doing good science and seem to have developed powerful scaffolds on which to build epigenetic compounds. So, perhaps a breakthrough could happen! Fun to think about.

As Don said, cancer trials move fast. But this is relative to CVD trials. At the end of the day it will take years but there could be a pot of gold at the end of the rainbow!

Sorry I couldn't help you re share price.

Cheers

Toinv

 

 

 

 

Share
New Message
Please login to post a reply